Analysts Anticipate Adaptimmune Therapeutics PLC – (ADAP) to Post -$0.03 EPS
Wall Street analysts expect Adaptimmune Therapeutics PLC – (NASDAQ:ADAP) to report earnings of ($0.03) per share for the current fiscal quarter, Zacks Investment Research reports. Three analysts have issued estimates for Adaptimmune Therapeutics’ earnings, with the highest EPS estimate coming in at $0.26 and the lowest estimate coming in at ($0.19). The business is scheduled to issue its next quarterly earnings results on Thursday, November 1st.
According to Zacks, analysts expect that Adaptimmune Therapeutics will report full-year earnings of ($1.02) per share for the current financial year, with EPS estimates ranging from ($1.27) to ($0.68). For the next year, analysts anticipate that the company will post earnings of ($1.25) per share, with EPS estimates ranging from ($1.56) to ($1.02). Zacks Investment Research’s EPS averages are a mean average based on a survey of analysts that that provide coverage for Adaptimmune Therapeutics.
Adaptimmune Therapeutics (NASDAQ:ADAP) last posted its earnings results on Thursday, August 2nd. The biotechnology company reported ($0.48) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.28) by ($0.20). Adaptimmune Therapeutics had a negative net margin of 191.14% and a negative return on equity of 47.22%. The company had revenue of $9.04 million for the quarter, compared to the consensus estimate of $7.76 million.
In other news, insider Gwendolyn Knowlt Binder-Scholl sold 25,000 shares of the business’s stock in a transaction that occurred on Monday, October 1st. The shares were sold at an average price of $13.79, for a total value of $344,750.00. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, major shareholder Enterprise Associates 14 New purchased 3,000,000 shares of the stock in a transaction dated Friday, September 7th. The stock was acquired at an average cost of $1.67 per share, for a total transaction of $5,010,000.00. The disclosure for this purchase can be found here. 26.47% of the stock is owned by insiders.
Several hedge funds and other institutional investors have recently bought and sold shares of ADAP. Millennium Management LLC raised its position in shares of Adaptimmune Therapeutics by 83.4% in the first quarter. Millennium Management LLC now owns 1,477,641 shares of the biotechnology company’s stock valued at $16,594,000 after purchasing an additional 672,046 shares during the period. Dorsey Wright & Associates bought a new stake in shares of Adaptimmune Therapeutics in the second quarter valued at approximately $6,981,000. Baillie Gifford & Co. raised its position in shares of Adaptimmune Therapeutics by 18.2% in the second quarter. Baillie Gifford & Co. now owns 3,033,261 shares of the biotechnology company’s stock valued at $36,005,000 after purchasing an additional 467,852 shares during the period. JPMorgan Chase & Co. raised its position in shares of Adaptimmune Therapeutics by 786.0% in the first quarter. JPMorgan Chase & Co. now owns 185,660 shares of the biotechnology company’s stock valued at $2,085,000 after purchasing an additional 164,704 shares during the period. Finally, Frontier Capital Management Co. LLC bought a new stake in shares of Adaptimmune Therapeutics in the second quarter valued at approximately $1,838,000. 59.32% of the stock is currently owned by institutional investors.
NASDAQ ADAP traded down $0.12 during trading on Tuesday, hitting $10.76. 594,791 shares of the company traded hands, compared to its average volume of 468,993. Adaptimmune Therapeutics has a 12 month low of $6.60 and a 12 month high of $14.63. The firm has a market cap of $1.02 billion, a P/E ratio of -13.45 and a beta of 1.07.
About Adaptimmune Therapeutics
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on the provision of cancer immunotherapy products based on its proprietary Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. Its platform enables in identifying cancer targets; finding and genetically engineering T-cell receptors (TCR); and producing TCR therapeutic candidates for administration to patients.
Further Reading: Day Trading
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Adaptimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.